Researchers developed COMPASS, an AI-driven system that functions as a temporal digital twin to model how normal tissues evolve during radiotherapy for non-small cell lung cancer (NSCLC). By analyzing high-frequency imaging and dosimetry data, COMPASS predicts toxicity risks several fractions before clinical symptoms appear, offering content creators insights into leveraging AI for personalized medicine and adaptive treatment strategies.
Read the full article at arXiv cs.CV (Vision)
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
11
Comments
AN
Ali NematiWritten by Ali
